

Foresight™ Carrier Screen disease list

The Counsyl Foresight Carrier Screen focuses on serious, clinically-actionable, and prevalent conditions to ensure you are providing meaningful information to your patients.

11-Beta-Hydroxylase-Deficient
Congenital Adrenal Hyperplasia
(*CYP11B1*)

21-Hydroxylase-Deficient
Congenital Adrenal Hyperplasia
(*CYP21A2*)*

6-Pyruvoyl-Tetrahydropterin
Synthase Deficiency (*PTS*)

ABCC8-Related Hyperinsulinism
(*ABCC8*)

Adenosine Deaminase Deficiency
(*ADA*)

Adrenoleukodystrophy: X-Linked
(*ABCD1*) X-linked

Alpha Thalassemia (*HBA1/HBA2*)*
ACOG ACMG

Alpha-Mannosidosis (*MAN2B1*)

Alpha-Sarcoglycanopathy
(including Limb-Girdle Muscular
Dystrophy, Type 2D) (*SGCA*)

Alport Syndrome, X-Linked
(*COL4A5*) X-linked

Alstrom Syndrome (*ALMS1*)

AMT-Related Glycine
Encephalopathy (*AMT*)

Andermann Syndrome (*SLC12A6*)

Argininemia (*ARG1*)

Argininosuccinic Aciduria (*ASL*)

ARSACS (*SACS*)

Aspartylglycosaminuria (*AGA*)

Ataxia with Vitamin E Deficiency
(*TTPA*)

Ataxia-Telangiectasia (*ATM*)

ATP7A-Related Disorders
(*ATP7A*) X-linked

Autosomal Recessive
Osteopetrosis, Type 1 (*TCIRG1*)

Bardet-Biedl Syndrome,
BBS1-Related (*BBS1*)

Bardet-Biedl Syndrome,
BBS10-Related (*BBS10*)

Bardet-Biedl Syndrome,
BBS12-Related (*BBS12*)

Bardet-Biedl Syndrome,
BBS2-Related (*BBS2*)

Beta-Sarcoglycanopathy
(including Limb-Girdle Muscular
Dystrophy, Type 2E) (*SGCB*)

Biotinidase Deficiency (*BTBD*)

Bloom Syndrome (*BLM*) ACMG

Calpainopathy (*CAPN3*)

Canavan Disease (*ASPA*) ACOG ACMG

Carbamoylphosphate Synthetase I
Deficiency (*CPS1*)

Carnitine Palmitoyltransferase IA
Deficiency (*CPT1A*)

Carnitine Palmitoyltransferase II
Deficiency (*CPT2*)

Cartilage-Hair Hypoplasia
(*RMRP*)

Cerebrotendinous Xanthomatosis
(*CYP27A1*)

Citrullinemia, Type 1 (*ASS1*)

CLN3-Related Neuronal Ceroid
Lipofuscinosis (*CLN3*)

CLN5-Related Neuronal Ceroid
Lipofuscinosis (*CLN5*)

CLN6-Neuronal Ceroid
Lipofuscinosis, Type 6 (*CLN6*)

Cohen Syndrome (*VPS13B*)

COL4A3-Related Alport
Syndrome (*COL4A3*)

COL4A4-Related Alport
Syndrome (*COL4A4*)

Congenital Disorder of
Glycosylation, Type Ia (*PMM2*)

Congenital Disorder of
Glycosylation, Type Ib (*MPI*)

Congenital Disorder of
Glycosylation, Type Ic (*ALG6*)

Congenital Finnish Nephrosis
(*NPHS1*)

Costeff Optic Atrophy Syndrome
(*OPA3*)

Cystic Fibrosis (*CFTR*) ACOG ACMG

Cystinosis (*CTNS*)

D-Bifunctional Protein Deficiency
(*HSD17B4*)

Delta-Sarcoglycanopathy (*SGCD*)

Dysferlinopathy (*DYSF*)

Dystrophinopathies (including
Duchenne/Becker Muscular
Dystrophy) (*DMD*) X-linked

ERCC6-Related Disorders (*ERCC6*)

ERCC8-Related Disorders (*ERCC8*)

EVC-Related Ellis-Van Creveld
Syndrome (*EVC*)

EVC2-Related Ellis-Van Creveld
Syndrome (*EVC2*)

Fabry Disease (*GLA*) X-linked

Familial Dysautonomia (*IKBKAP*)
ACOG ACMG

Familial Mediterranean Fever
(*MEFV*)

Fanconi Anemia Complementation,
Group A (*FANCA*)

Fanconi Anemia, Type C
(*FANCC*) ACMG

FKRP-Related Disorders (*FKRP*)

FKTN-Related Disorders
(including Walker-Warburg
Syndrome) (*FKTN*)

Fragile X Syndrome (*FMR1*)*
X-linked

Galactokinase Deficiency
(*GALK1*)

Galactosemia (*GALT*)

Gamma-Sarcoglycanopathy
(*SGCG*)

Gaucher Disease (*GBA*)* ACMG

GJB2-Related DFNB1

Nonsyndromic Hearing Loss and
Deafness (including two GJB6
deletions) (*GJB2*)

GLB1-Related Disorders (*GLB1*)

GLDC-Related Glycine
Encephalopathy (*GLDC*)

Glutaric Acidemia, Type 1 (*GCDH*)

Glycogen Storage Disease,
Type Ia (*G6PC*)

Glycogen Storage Disease,
Type Ib (*SLC37A4*)

Glycogen Storage Disease,
Type III (*AGL*)

GNPTAB-Related Disorders
(*GNPTAB*)

GRACILE Syndrome (*BCS1L*)

HADHA-Related Disorders
(including Long Chain
3-Hydroxyacyl-CoA
Dehydrogenase Deficiency)
(*HADHA*)

Hb Beta Chain-Related
Hemoglobinopathy (including
Beta Thalassemia and Sickle Cell
Disease) (*HBB*) ACOG

Hereditary Fructose Intolerance
(*ALDOB*)

Herlitz Junctional Epidermolysis
Bullosa, LAMA3-Related
(*LAMA3*)

Herlitz Junctional Epidermolysis
Bullosa, LAMB3-Related (*LAMB3*)

Herlitz Junctional Epidermolysis
Bullosa, LAMC2-related (*LAMC2*)

Hexosaminidase A Deficiency
(including Tay-Sachs Disease)
(*HEXA*) ACOG ACMG

HMG-CoA Lyase Deficiency
(*HMGCL*)

| | | | |
|--|--|--|---|
| Holocarboxylase Synthetase Deficiency (<i>HLCS</i>) | Mucopolipidosis IV (<i>MCOLN1</i>) ACMG | PEX1-Related Zellweger Syndrome Spectrum (<i>PEX1</i>) | Sulfate Transporter-Related Osteochondrodysplasia (<i>SLC26A2</i>) |
| Homocystinuria caused by Cystathionine Beta-Synthase Deficiency (<i>CBS</i>) | Mucopolysaccharidosis, Type I (including Hurler Syndrome) (<i>IDUA</i>) | Phenylalanine Hydroxylase Deficiency (<i>PAH</i>) | TGM1-Related Autosomal Recessive Congenital Ichthyosis (<i>TGM1</i>) |
| Hydroletharus Syndrome (<i>HYLS1</i>) | Mucopolysaccharidosis, Type II (<i>IDS</i>) X-linked | PKHD1-Related Autosomal Recessive Polycystic Kidney Disease (<i>PKHD1</i>) | TPP1-Related Neuronal Ceroid Lipofuscinosis (<i>TPP1</i>) |
| Hypophosphatasia, Autosomal Recessive (<i>ALPL</i>) | Mucopolysaccharidosis, Type IIIA (<i>SGSH</i>) | Polyglandular Autoimmune Syndrome, Type 1 (<i>AIRE</i>) | Tyrosinemia, Type I (<i>FAH</i>) |
| Inclusion Body Myopathy 2 (<i>GNE</i>) | Mucopolysaccharidosis, Type IIIB (<i>NAGLU</i>) | Pompe Disease (<i>GAA</i>) | Tyrosinemia, Type II (<i>TAT</i>) |
| Isovaleric Acidemia (<i>IVD</i>) | Mucopolysaccharidosis, Type IIIC (<i>HGSNAT</i>) | PPT1-Related Neuronal Ceroid Lipofuscinosis (<i>PPT1</i>) | USH1C-Related Disorders (<i>USH1C</i>) |
| Joubert Syndrome 2 (<i>TMEM216</i>) | Muscle-Eye-Brain Disease (<i>POMGNT1</i>) | Primary Carnitine Deficiency (<i>SLC22A5</i>) | USH2A-Related Disorders (<i>USH2A</i>) |
| KCNJ11-Related Familial Hyperinsulinism (<i>KCNJ11</i>) | MUT-Related Methylmalonic Acidemia (<i>MUT</i>) | Primary Hyperoxaluria, Type 1 (<i>AGXT</i>) | Usher Syndrome, Type 3 (<i>CLRN1</i>) |
| Krabbe Disease (<i>GALC</i>) | MYO7A-Related Disorders (<i>MYO7A</i>) | Primary Hyperoxaluria, Type 2 (<i>GRHPR</i>) | Very Long Chain Acyl-CoA Dehydrogenase Deficiency (<i>ACADVL</i>) |
| LAMA2-Related Muscular Dystrophy (<i>LAMA2</i>) | NEB-Related Nemaline Myopathy (<i>NEB</i>) | Primary Hyperoxaluria, Type 3 (<i>HOGA1</i>) | Wilson Disease (<i>ATP7B</i>) |
| Leigh Syndrome, French-Canadian Type (<i>LRPPRC</i>) | Niemann-Pick Disease, Type C (<i>NPC1</i>) | PROP1-Related Combined Pituitary Hormone Deficiency (<i>PROPT</i>) | X-Linked Congenital Adrenal Hypoplasia (<i>NROB1</i>) X-linked |
| Lipoamide Dehydrogenase Deficiency (<i>DLD</i>) | Niemann-Pick Disease, Type C2 (<i>NPC2</i>) | Pycnodysostosis (<i>CTSK</i>) | X-Linked Juvenile Retinoschisis (<i>RS1</i>) X-linked |
| Lipoid Congenital Adrenal Hyperplasia (<i>STAR</i>) | Niemann-Pick Disease, SMPD1-Associated (<i>SMPD1</i>) ACMG | Pyruvate Carboxylase Deficiency (<i>PC</i>) | X-Linked Myotubular Myopathy (<i>MTM1</i>) X-linked |
| Lysosomal Acid Lipase Deficiency (<i>LIPA</i>) | Nijmegen Breakage Syndrome (<i>NBN</i>) | Rhizomelic Chondrodysplasia Punctata, Type 1 (<i>PEX7</i>) | X-Linked Severe Combined Immunodeficiency (<i>IL2RG</i>) X-linked |
| Maple Syrup Urine Disease, Type Ia (<i>BCKDHA</i>) | Northern Epilepsy (<i>CLN8</i>) | RTEL1-Related Disorders (<i>RTEL1</i>) | Xeroderma Pigmentosum, Group A (<i>XPA</i>) |
| Maple Syrup Urine Disease, Type IB (<i>BCKDHB</i>) | Ornithine Transcarbamylase Deficiency (<i>OTC</i>) X-linked | Salla Disease (<i>SLC17A5</i>) | Xeroderma Pigmentosum, Group C (<i>XPC</i>) |
| Maple Syrup Urine Disease, Type II (<i>DBT</i>) | PCCA-Related Propionic Acidemia (<i>PCCA</i>) | Sandhoff Disease (<i>HEXB</i>) | |
| Medium Chain Acyl-CoA Dehydrogenase Deficiency (<i>ACADM</i>) | PCCB-Related Propionic Acidemia (<i>PCCB</i>) | Segawa Syndrome (<i>TH</i>) | |
| Megalencephalic Leukoencephalopathy with Subcortical Cysts (<i>MLC1</i>) | PCDH15-Related Disorders (including Usher Syndrome, Type 1F) (<i>PCDH15</i>) | Short Chain Acyl-CoA Dehydrogenase Deficiency (<i>ACADS</i>) | |
| Metachromatic Leukodystrophy (<i>ARSA</i>) | Pendred Syndrome (<i>SLC26A4</i>) | Sjogren-Larsson Syndrome (<i>ALDH3A2</i>) | ACOG Indicates testing recommended by ACOG |
| Methylmalonic Acidemia, cblA Type (<i>MMAA</i>) | Peroxisome Biogenesis Disorder, Type 3 (<i>PEX12</i>) | Smith-Lemli-Opitz Syndrome (<i>DHCR7</i>) | ACMG Indicates testing recommended by ACMG |
| Methylmalonic Acidemia, cblB Type (<i>MMAB</i>) | Peroxisome Biogenesis Disorder, Type 4 (<i>PEX6</i>) | Spastic Paraplegia, Type 15 (<i>ZFYVE26</i>) | X-linked Indicates X-linked disorders |
| Methylmalonic Aciduria and Homocystinuria, cblC Type (<i>MMACHC</i>) | Peroxisome Biogenesis Disorder, Type 5 (<i>PEX2</i>) | Spinal Muscular Atrophy (<i>SMN1</i>)* ACOG ACMG | |
| MKS1-Related Disorders (<i>MKS1</i>) | Peroxisome Biogenesis Disorder, Type 6 (<i>PEX10</i>) | Spondylothoracic Dysostosis (<i>MESP2</i>) | |
| Mucopolipidosis III Gamma (<i>GNPTG</i>) | | Steroid-Resistant Nephrotic Syndrome (<i>NPHS2</i>) | |

*Analyzed using custom assay